🇺🇸 FDA
Pipeline program

Obinutuzumab

232516

Phase 2 mab active

Quick answer

Obinutuzumab for Mantle Cell Lymphoma is a Phase 2 program (mab) at Adaptive Biotechnologies Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
Adaptive Biotechnologies Corp
Indication
Mantle Cell Lymphoma
Phase
Phase 2
Modality
mab
Status
active

Clinical trials